Disturbed lipid and amino acid metabolisms in COVID-19 patients
Standard
Disturbed lipid and amino acid metabolisms in COVID-19 patients. / Masoodi, Mojgan; Peschka, Manuela; Schmiedel, Stefan; Haddad, Munif; Frye, Maike; Maas, Coen; Lohse, Ansgar; Huber, Samuel; Kirchhof, Paulus; Nofer, Jerzy-Roch; Renné, Thomas.
in: J MOL MED, Jahrgang 100, Nr. 4, 04.2022, S. 555-568.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Disturbed lipid and amino acid metabolisms in COVID-19 patients
AU - Masoodi, Mojgan
AU - Peschka, Manuela
AU - Schmiedel, Stefan
AU - Haddad, Munif
AU - Frye, Maike
AU - Maas, Coen
AU - Lohse, Ansgar
AU - Huber, Samuel
AU - Kirchhof, Paulus
AU - Nofer, Jerzy-Roch
AU - Renné, Thomas
N1 - © 2022. The Author(s).
PY - 2022/4
Y1 - 2022/4
N2 - The Coronavirus disease 2019 (COVID-19) pandemic is overwhelming the healthcare systems. Identification of systemic reactions underlying COVID-19 will lead to new biomarkers and therapeutic targets for monitoring and early intervention in this viral infection. We performed targeted metabolomics covering up to 630 metabolites within several key metabolic pathways in plasma samples of 20 hospitalized COVID-19 patients and 37 matched controls. Plasma metabolic signatures specifically differentiated severe COVID-19 from control patients. The identified metabolic signatures indicated distinct alterations in both lipid and amino acid metabolisms in COVID-19 compared to control patient plasma. Systems biology-based analyses identified sphingolipid, tryptophan, tyrosine, glutamine, arginine, and arachidonic acid metabolism as mostly impacted pathways in COVID-19 patients. Notably, gamma-aminobutyric acid (GABA) was significantly reduced in COVID-19 patients and GABA plasma levels allowed for stratification of COVID-19 patients with high sensitivity and specificity. The data reveal large metabolic disturbances in COVID-19 patients and suggest use of GABA as potential biomarker and therapeutic target for the infection.
AB - The Coronavirus disease 2019 (COVID-19) pandemic is overwhelming the healthcare systems. Identification of systemic reactions underlying COVID-19 will lead to new biomarkers and therapeutic targets for monitoring and early intervention in this viral infection. We performed targeted metabolomics covering up to 630 metabolites within several key metabolic pathways in plasma samples of 20 hospitalized COVID-19 patients and 37 matched controls. Plasma metabolic signatures specifically differentiated severe COVID-19 from control patients. The identified metabolic signatures indicated distinct alterations in both lipid and amino acid metabolisms in COVID-19 compared to control patient plasma. Systems biology-based analyses identified sphingolipid, tryptophan, tyrosine, glutamine, arginine, and arachidonic acid metabolism as mostly impacted pathways in COVID-19 patients. Notably, gamma-aminobutyric acid (GABA) was significantly reduced in COVID-19 patients and GABA plasma levels allowed for stratification of COVID-19 patients with high sensitivity and specificity. The data reveal large metabolic disturbances in COVID-19 patients and suggest use of GABA as potential biomarker and therapeutic target for the infection.
U2 - 10.1007/s00109-022-02177-4
DO - 10.1007/s00109-022-02177-4
M3 - SCORING: Journal article
C2 - 35064792
VL - 100
SP - 555
EP - 568
JO - J MOL MED
JF - J MOL MED
SN - 0946-2716
IS - 4
ER -